BCDA

BioCardia, Inc. Common Stock (BCDA) | Rumor.io

BioCardia

BCDA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,033

Bullish sentiment (50-day avg)99%

Price to earnings ratio-0.86

Market capitalization15.7M

Earnings per share-0.59

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-8.2M

Social

What share of all stock conversation is about BCDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 22

BioCardia, Inc. ($BCDA) may have a $4M capital raise via ATM without warrants, and a recent trading pattern suggests a major event is unfolding.
The company is preparing a Shonin pre-market regulatory submission to Japan's PMDA for approval of CardiAMP Cell Therapy for ischemic heart failure, with a targeted approval in Q4 2026.
BioCardia has regained Nasdaq minimum bid price compliance after a 10-day threshold, and the company's recent earnings call and upcoming events may provide more clarity on its progress.

Generated by AI

Sentiment

Of the messages about BCDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	95.12% -4.58	95.42% +6.19
Bearish	—	0% 0	4.88% +4.58	4.58% -6.19

Bullish· Jun 5

The company has seen significant price increases, with one post mentioning a 52% gain and another mentioning a potential 300% increase following an announcement.
There is a strong expectation that the company's stock will continue to rise, with several posts mentioning potential price targets of $1.45, $2, and $15.
The company's FDA approval is seen as a key catalyst for its stock, with one post suggesting that it could lead to a significant explosion in the stock's price.

Bearish· Jun 5

The price of $BCDA is expected to be history and will go over $10.00.
BioCardia, Inc. is experiencing a decline in its stock price, with some predicting a double-digit drop by the end of the day.
The company is facing challenges, including dilution and a lack of credibility, which may lead to further price declines.

Generated by AI

Topics

Of the messages about BCDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	58.68%
Technical Analysis	—	0%	0%	4.53%
Analysts	—	0%	0%	16.97%
Controversies	—	0%	0%	0.13%
Earnings	—	0%	0%	0.13%
Macro	—	0%	0%	19.56%

Announcements· Jun 5

BioCardia, Inc. (BCDA) announced receipt of FDA minutes from a Q-Sub meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
The FDA confirmed that the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) of the CardiAMP Cell Therapy System for ischemic HFrEF, providing a clearer path to approval.
BioCardia is well-positioned to deliver a groundbreaking treatment for ischemic heart failure patients, with the FDA already recognizing the therapy as safe and acknowledging a potential market of over one million patients in the U.S.

Technical Analysis· Aug 29

$BCDA has held its uptrend and may reach $6.06 with the 200-day moving average.
The cup-and-handle chart pattern suggests a bullish continuation, with the handle duration potentially being a quarter to a half of the cup duration.
Breakout points for $BCDA include $3.66, $4.80, and $6.20, with potential targets of $10-20.

Generated by AI

Community

Of the messages about BCDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75%	68.18%	33.53%
Newcomers	—	25%	31.82%	66.47%

Regulars· Sep 18

BioCardia's CardiAMP Cell Therapy showed significant improvements in exercise tolerance and a reduction in angina episodes for patients with chronic myocardial ischemia.
The company has announced positive top-line data from the roll-in cohort of its CardiAMP Chronic Myocardial Ischemia Trial, with improved exercise tolerance and reduced angina episodes at six-month primary follow-up.
BioCardia has priced a public offering of up to $12 million at $1.25 per share, with 4.8 million shares of common stock and short-term warrants to be sold.

Newcomers· Jun 5

Many newcomers are tempted to invest in BCDA, but are worried about the high risk of losing money in biotech stocks.
The FDA's confirmation of the CardiAMP trial path is seen as a major positive development for BCDA, potentially leading to a significant increase in the stock's value.
Newcomers are focusing on the stock's recent price movement, with some calling for a buy or sell, while others are speculating about the potential for BCDA to "fly" or be a "winner".

Generated by AI

News

BioCardia CEO Peter Altman buys $1,995 in stock

6d agoInvesting.com

BioCardia targets Japan regulatory submission in Q4 2026

6d agoInvesting.com

BioCardia Shares Fall 10% After Hours: Here's Why - BioCardia (NASDAQ:BCDA)

BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.

8d agoBenzinga

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026. Dr. Altman will provide an update

20d agoYahoo Finance

BioCardia CEO Peter Altman buys $872 in company stock

25d agoInvesting.com

BioCardia receives FDA confirmation on Helix catheter meeting

1mo agoInvesting.com

Also Discussed

Investors talking about BCDA also mention

#	Name	Attention
1	ParaZero Technologies Ltd.PRZO	0%+0
2	Naya Biosciences Inc.INVO	0%0
3	HeartSciences Inc.HSCS	0%0
4	MSPR - MSP Recovery, Inc.	——
5	Apollomics Inc.APLM	0%0
6	Cardio Diagnostics Holdings, Inc.CDIO	0%0
7	Lixte Biotechnology Holdings Inc.LIXT	0%new
8	China Natural Resources, Inc. Common StockCHNR	0%new
9	Nuvectis Pharma, Inc.NVCT	0%0
10	FNCH - Finch Therapeutics Group, Inc.	——

BioCardia, Inc. Common Stock

Healthcare
Biotechnology

BioCardia, Inc. Common Stock represents an investment in BioCardia, a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. BioCardia’s current product portfolio centers on autologous and allogeneic cell therapy platforms, including CardiAMP and CardiALLO, which are designed to address unmet needs in heart failure and other serious cardiac conditions. The company also develops enabling medical technologies such as the Helix biotherapeutic delivery system and the Morph line of steerable guide and sheath products, which support precise delivery of therapeutic agents and procedures in cardiovascular care. BioCardia operates in the biotechnology and healthcare markets, where its work combines cell processing, targeted delivery, and regenerative therapy development for clinical use. Headquartered in Sunnyvale, California, BioCardia serves as a specialized participant in the broader field of advanced biologic and device-based cardiovascular treatment solutions.

Website

Location

320 Soquel Way

Sunnyvale, CA, 94085

United States

Social

What share of all stock conversation is about BCDA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Sep 22

BioCardia, Inc. ($BCDA) may have a $4M capital raise via ATM without warrants, and a recent trading pattern suggests a major event is unfolding.
The company is preparing a Shonin pre-market regulatory submission to Japan's PMDA for approval of CardiAMP Cell Therapy for ischemic heart failure, with a targeted approval in Q4 2026.
BioCardia has regained Nasdaq minimum bid price compliance after a 10-day threshold, and the company's recent earnings call and upcoming events may provide more clarity on its progress.

Generated by AI

Sentiment

Of the messages about BCDA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	95.12% -4.58	95.42% +6.19
Bearish	—	0% 0	4.88% +4.58	4.58% -6.19

Bullish· Jun 5

The company has seen significant price increases, with one post mentioning a 52% gain and another mentioning a potential 300% increase following an announcement.
There is a strong expectation that the company's stock will continue to rise, with several posts mentioning potential price targets of $1.45, $2, and $15.
The company's FDA approval is seen as a key catalyst for its stock, with one post suggesting that it could lead to a significant explosion in the stock's price.

Bearish· Jun 5

The price of $BCDA is expected to be history and will go over $10.00.
BioCardia, Inc. is experiencing a decline in its stock price, with some predicting a double-digit drop by the end of the day.
The company is facing challenges, including dilution and a lack of credibility, which may lead to further price declines.

Generated by AI

Topics

Of the messages about BCDA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	58.68%
Technical Analysis	—	0%	0%	4.53%
Analysts	—	0%	0%	16.97%
Controversies	—	0%	0%	0.13%
Earnings	—	0%	0%	0.13%
Macro	—	0%	0%	19.56%

Announcements· Jun 5

BioCardia, Inc. (BCDA) announced receipt of FDA minutes from a Q-Sub meeting with FDA Center for Biologics Evaluation and Research (CBER) on the CardiAMP Cell Therapy System for the treatment of ischemic heart failure of reduced ejection fraction (HFrEF).
The FDA confirmed that the ongoing CardiAMP Heart Failure II Trial may support Premarket Approval (PMA) of the CardiAMP Cell Therapy System for ischemic HFrEF, providing a clearer path to approval.
BioCardia is well-positioned to deliver a groundbreaking treatment for ischemic heart failure patients, with the FDA already recognizing the therapy as safe and acknowledging a potential market of over one million patients in the U.S.

Technical Analysis· Aug 29

$BCDA has held its uptrend and may reach $6.06 with the 200-day moving average.
The cup-and-handle chart pattern suggests a bullish continuation, with the handle duration potentially being a quarter to a half of the cup duration.
Breakout points for $BCDA include $3.66, $4.80, and $6.20, with potential targets of $10-20.

Generated by AI

Community

Of the messages about BCDA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	75%	68.18%	33.53%
Newcomers	—	25%	31.82%	66.47%

Regulars· Sep 18

BioCardia's CardiAMP Cell Therapy showed significant improvements in exercise tolerance and a reduction in angina episodes for patients with chronic myocardial ischemia.
The company has announced positive top-line data from the roll-in cohort of its CardiAMP Chronic Myocardial Ischemia Trial, with improved exercise tolerance and reduced angina episodes at six-month primary follow-up.
BioCardia has priced a public offering of up to $12 million at $1.25 per share, with 4.8 million shares of common stock and short-term warrants to be sold.

Newcomers· Jun 5

Many newcomers are tempted to invest in BCDA, but are worried about the high risk of losing money in biotech stocks.
The FDA's confirmation of the CardiAMP trial path is seen as a major positive development for BCDA, potentially leading to a significant increase in the stock's value.
Newcomers are focusing on the stock's recent price movement, with some calling for a buy or sell, while others are speculating about the potential for BCDA to "fly" or be a "winner".

Generated by AI

BioCardia

Social

Sep 22

Bullish· Jun 5

Bearish· Jun 5

Announcements· Jun 5

Technical Analysis· Aug 29

Regulars· Sep 18

Newcomers· Jun 5

BioCardia CEO Peter Altman buys $1,995 in stock

BioCardia targets Japan regulatory submission in Q4 2026

BioCardia Shares Fall 10% After Hours: Here's Why - BioCardia (NASDAQ:BCDA)

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

BioCardia CEO Peter Altman buys $872 in company stock

BioCardia receives FDA confirmation on Helix catheter meeting

Also Discussed

BioCardia, Inc. Common Stock

Company Information

Location

BioCardia CEO Peter Altman buys $1,995 in stock

BioCardia targets Japan regulatory submission in Q4 2026

BioCardia Shares Fall 10% After Hours: Here's Why - BioCardia (NASDAQ:BCDA)

BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

BioCardia CEO Peter Altman buys $872 in company stock

BioCardia receives FDA confirmation on Helix catheter meeting

Also Discussed

Social

Sep 22

Bullish· Jun 5

Bearish· Jun 5

Announcements· Jun 5

Technical Analysis· Aug 29

Regulars· Sep 18

Newcomers· Jun 5